M. Gilliom

interleukin-2 receptor expression in a phase II study fungoides and the Sezary syndrome: correlation of activity and Chimeric fusion protein toxin DAB486IL-2 in advanced mycosis

M. Stetler-Stevenson, T. Woodworth, P. Nylen, 2011 .

Chimeric fusion protein toxin DAB486IL-2 in advanced mycosis fungoides and the Sezary syndrome: correlation of activity and interleukin-2 receptor expression in a phase II study.

E. Jaffe, M. Stetler-Stevenson, W. Figg, 1994, Blood.

Chimeric fusion protein toxin DAB486IL-2 in advanced mycosis fungoides and the Sezary syndrome: correlation of activity and interleukin-2 receptor expression in a phase II study.

Figg, E. Jaffe, E. Sausville, 1994, Blood.

Treatment of localized aggressive lymphomas with combination chemotherapy followed by involved-field radiation therapy.

E. Jaffe, R. Fisher, P. Duffey, 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Vancomycin is not an essential component of the initial empiric treatment regimen for febrile neutropenic patients receiving ceftazidime: a randomized prospective study

B. Kramer, J. D. Malone, R. Ramphal, 1992, Antimicrobial Agents and Chemotherapy.

Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial.

E. Jaffe, R. Fisher, P. Duffey, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Etoposide (VP-16) and cisplatin in previously treated small-cell lung cancer: clinical trial and in vitro correlates.

P. Bunn, G. Batist, K. Cowan, 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.